Gilead Sciences Inc

$170,12$2,54 (+1,52 %)
Last updated on --.

Gilead Sciences Inc price

24 Hours+1,52 %+$2,540
30 days+9,50 %+$14,54
60 days+11,66 %+$17,5
90 days+13,56 %+$20,01

About Gilead Sciences Inc

Gilead Sciences, Inc. er et globalt biofarmasøytisk selskap med virksomhet i USA, Europa og en rekke internasjonale markeder. Deres kjerneoppdrag er å oppdage, utvikle og kommersialisere innovative medisiner for å møte kritiske helsebehov. Selskapets omfattende produktportefølje inkluderer behandlinger for en rekke alvorlige tilstander. For HIV/AIDS leverer de viktige terapier som Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild og Atripla. Som respons på koronaviruspandemien i 2019 tilbyr Gilead Veklury, et injiserbart legemiddel for intravenøs administrasjon. Deres tilbud for leversykdommer inkluderer Epclusa, Harvoni, Vosevi, Vemlidy og Viread. Videre hjelper Gilead pasienter som kjemper mot hematologiske lidelser, ulike kreftformer og de som gjennomgår celleterapi, med produkter som Yescarta, Tecartus, Trodelvy og Zydelig. Andre spesialiserte medisiner inkluderer Letairis, et oralt legemiddel for pulmonal arteriell hypertensjon; Ranexa, også et oralt legemiddel, for kronisk angina; og AmBisome, en liposomal formulering designet for å bekjempe alvorlige invasive soppinfeksjoner. Gilead Sciences, Inc. deltar aktivt i samarbeidsavtaler med et bredt spekter av partnere for å fremme sin terapeutiske pipeline. Disse inkluderer Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., og Merck & Co, Inc. Selskapet ble grunnlagt i 1987, og hovedkontoret ligger i Foster City, California.

Aksjesymbol
GILD
Selskap
Gilead Sciences, Inc.
Industri
Helsevesenet
Kategori
US
Aksjesplitt / omvendt splitt
12
Lanseringsdato
22. jan. 1992
Notert børs
NASDAQ

Finansielle forhold

Q3 FY2026 Resultater
Rapportperiode: 1. juli 2026 – 30. sep. 2026

Sammendrag: GILD reported Revenue of 8.30B (+6,83 %), beating expectations; EPS of 2,55 (+3,24 %), beating expectations.

Inntekt (USD)Slå8,30 mrd.+6,83 %7,81 mrd.+4,83 %494,51 mill.+6,33 %
EPS (USD)Slå2,55+3,23 %2,19+2,81 %0,36+16,43 %
Finansielle estimater
● Faktisk● Estimere
Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
2,431,741,61−-8,451,94
+143,00 %+22,53 %+54,80 %−641,67 %−20,17 %
● EPS● YoY
Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
58,53 mrd.59,02 mrd.56,28 mrd.49,36 mrd.51,41 mrd.
37,08 mrd.36,41 mrd.32,85 mrd.37,62 mrd.38,45 mrd.
63,34 %61,67 %58,36 %76,20 %74,79 %
● Eiendeler● Forpliktelser● Forhold
Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
4,11 mrd.3,33 mrd.2,54 mrd.3,57 mrd.5,04 mrd.
−4,67 %+11,83 %+44,79 %+332,04 %+22,59 %
● CFO● YoY

Aksjonærer

Aksjonærer
BLACKROCK, INC.9,80 %
VANGUARD CAPITAL MANAGEMENT LLC6,52 %
FMR LLC5,37 %
STATE STREET CORP4,92 %
CAPITAL WORLD INVESTORS3,29 %
Andre70,06 %
Institusjoner
% Eiet90,18 %+3,71 %
Aksjer holdt1,12 mrd.+46,17 mill.
Institusjoner2 373-34
% EietPris
Navn% EietEndre
BLACKROCK, INC.9,80 %+2,83 mill.
VANGUARD CAPITAL MANAGEMENT LLC6,52 %+436,96k
FMR LLC5,37 %−-5,04 mill.
STATE STREET CORP4,92 %+1,36 mill.
CAPITAL WORLD INVESTORS3,29 %−-294,96k

Utbytte

Utbytte
Siste eks-utbytte: 15. des. 2026 Kontantutbytte: 0,82 USD per aksje
Utbytteavkastning TTM
2,39 %
Utbetalingsgrad LFY
46,60 %
Frekvens
Kvartalsvis
20222023202420252026
2,923,003,083,163,28
+3,30 %+3,66 %+3,35 %+2,63 %+1,94 %
Dividend amount (USD)Utbytteavkastning
Aksjesplittelser
Lanseringsdato: 22. jan. 1992
DatoForhold
28. jan. 20131 → 2
25. juni 20071 → 2
7. sep. 20041 → 2
8. mars 20021 → 2
22. feb. 20011 → 2

Gilead Sciences Inc conversion tables

GILDGILD
USDUSD
0.5 GILD85,06 USD
1 GILD170,12 USD
5 GILD850,6 USD
10 GILD1 701,2 USD
USDUSD
GILDGILD
0.5 USD0,0029391 GILD
1 USD0,0058782 GILD
5 USD0,029391 GILD
10 USD0,058782 GILD

More to explore

FAQ

GILD is trading at $170,12, +1,52 % over the last 24 hours. Track live moves on the price chart at the top of this page.

The GILD stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. GILD is currently trading at $170,12, +1,52 % over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on GILD price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Helsevesenet sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.

P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. GILD's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from GILD; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against GILD's historical range and other companies in the Helsevesenet sector.

Gilead Sciences, Inc.'s market cap is currently 210,91 mrd. USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.